EA5181 Phase 3 Trial Shows No Overall Survival Advantage for Concurrent Plus Consolidative Durvalumab Over Consolidation Alone in Unresectable Stage 3 NSCLC
(Barcelona, Spain – September 8, 2025, 10:45 a.m. CEST / UTC +2) — In a pivotal development presented at the ...
